483 related articles for article (PubMed ID: 9032579)
1. New NSAIDs and gastroduodenal damage.
Folco GC
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
[TBL] [Abstract][Full Text] [Related]
2. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
Dammann HG
Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
[TBL] [Abstract][Full Text] [Related]
3. New directions in cyclooxygenase research and their implications for NSAID-gastropathy.
Flower RJ
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():23-7. PubMed ID: 9032578
[TBL] [Abstract][Full Text] [Related]
4. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
5. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
Tada Y; Nagasawa K
Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
[TBL] [Abstract][Full Text] [Related]
6. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
Hinz B; Brune K
Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
[TBL] [Abstract][Full Text] [Related]
7. COX-1 and COX-2 inhibitors.
Hawkey CJ
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
[TBL] [Abstract][Full Text] [Related]
8. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of NSAID-induced gastroduodenal mucosal injury.
Wallace JL
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):691-703. PubMed ID: 11566035
[TBL] [Abstract][Full Text] [Related]
10. [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
Laudanno OM; Cesolari JA; Esnarriaga J; Flaherty P; Vada J; Guastalli G; San Miguel P; Bedini OA
Acta Gastroenterol Latinoam; 1998; 28(3):249-55. PubMed ID: 9773153
[TBL] [Abstract][Full Text] [Related]
11. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
12. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Bannwarth B
Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148
[No Abstract] [Full Text] [Related]
13. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
14. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
15. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
[No Abstract] [Full Text] [Related]
16. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
Pairet M; Netter P
Therapie; 1999; 54(4):433-45. PubMed ID: 10667110
[TBL] [Abstract][Full Text] [Related]
17. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
18. [Are COX-2 inhibitors truly able to prevent NSAIDs-associated ulcer?].
Nishida T; Tsujii M; Tsuji S
Nihon Rinsho; 2004 Mar; 62(3):561-5. PubMed ID: 15038104
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors.
Brooks PM; Day RO
Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of inhibition OF COX-2 and COX-3 in gastrointestinal damage induced by NSAID in rats ].
Laudanno OM; San Miguel P; Aramberry LJ; Cesolari JA
Acta Gastroenterol Latinoam; 2003; 33(4):183-5. PubMed ID: 14708469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
